

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
19.07.2000 Bulletin 2000/29

(51) Int Cl.7: **A61K 31/57, C07J 13/00,**
C07J 7/00

(21) Application number: **99302556.8**

(22) Date of filing: **31.03.1999**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
 Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **12.01.1999 IN 6799**

(71) Applicant: **Council of Scientific and**
Industrial Research
New Delhi 110 001 (IN)


(72) Inventors:
 • **Pratap, Ram**
Lucknow 226 001 U.P. (IN)
 • **Gupta, Ram Chandra**
Lucknow 226 001 U.P. (IN)
 • **Chander, Ramesh**
Lucknow 226 001 U.P. (IN)
 • **Khanna, Ashok Kumar**
Lucknow 226 001 U.P. (IN)
 • **Srivastava, Arvind Kumar**
Lucknow 226 001 U.P. (IN)
 • **Raina, Deepak**
Lucknow 226 001 U.P. (IN)

- **Singh, Satyavan**
Lucknow 226 001 U.P. (IN)
- **Srivastava, Savita**
Lucknow 226 001 U.P. (IN)
- **Rastogi, Anil Kumar**
Lucknow 226 001 U.P. (IN)
- **Asthana, Omkar Prasad**
Lucknow 226 001 U.P. (IN)
- **Nityanand, Swarna**
Lucknow 226 001 U.P. (IN)
- **Anand, Nitya**
Lucknow 226 001 U.P. (IN)
- **Ghatak, Ashim**
Lucknow 226 001 U.P. (IN)
- **Kapoor, Narinder Kumar**
Lucknow 226 001 U.P. (IN)
- **Dev, Sukh**
Lucknow 226 001 U.P. (IN)

(74) Representative: **Florence, Julia Anne et al**
Kilburn & Strode,
20 Red Lion Street
London WC1R 4PJ (GB)

(54) **Medicaments for hypolipidemic and hypoglycemic conditions**

(57) The invention provides a method of using pregnadienones and pregnadienols represented by the structural formula (I) as shown herein below



Wherein X=OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 6(17); 17(20) or various combinations and said compounds containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to the recipient mammals.

Description**Field of the Invention**

5 [0001] This invention relates to the novel use of D-ring unsaturated pregnadienols/ pregnadienones represented by general formula I as shown in the accompanying drawings, possessing both pronounced hypolipidemic and hypoglycemic activities and devoid of androgenic and progestational activities. More particularly this invention relates to the novel use of 3 β -hydroxy-pregna-5, 16-dienone an important prototype of this class, represented by the formula (II) as shown in the accompanying drawings, for the treatment of diabetes and pronounced hypolipidemic and hypoglycemic activities.

Background

15 [0002] High plasma cholesterol and related lipids are known to be one of the factors that predispose an individual to atherosclerosis and thus to myocardial infarction. Diabetes mellitus, which eventually impairs the function of kidneys, eyes, nervous and vascular systems, is quite often associated with lipid disorders. Both hyperlipidemia and diabetes mellitus require long term management and pose problems in choice of pharmacotherapeutic interventions when these conditions manifest together. Though a number of drugs are known separately to treat these conditions, there are a number of side effects associated with them which limit their long term use.

20 [0003] The most important hypolipidemic drugs available today belong to the statin and fibrate classes [McCarthy, P.A., Med. Res. Rev., 13, 139-59 (1993)] whereas hypoglycemic drugs fall into the category of sulphonylureas, biguanidines and amidines [Wolff, M.E. (Ed), Burger's Medicinal Chemistry Part II, 1045 (1981), John Wiley & Sons, New York]. However, these therapeutic agents are not free of side effects-statins (HMG-CoA reductase inhibitors) the most widely used drugs today which hitherto were thought to be very safe drugs, have exhibited side effects following long term therapy [Carrier, M. et al.; Ann. Thorac. Surg., 57, 353-6 (1994)]. The adverse effects which have become the source of concern, are increases in hepatic transaminases and myopathies [Witztum, J.L., In Goodman & Gilman's The Pharmacological Basis of Therapeutics, eds. Hardman, J. et al., 9th edition, McGraw Hill, New York pp. 875-98, Fukami, M. et al; Res. Exp. Med., 193, 263-73 (1993); Appelkvist, E., et al.; Clin. Invest., 71 (suppl 8), 597-102 (1993), Wills, R.A. et al.; Proc. Natl. Acad. Sci. (US), 87, 8928-30 (1990)] and carcinogenesis specially breast cancer in subjects undergoing treatment with pravastatin [Braunwald, E.; Scrip, 2117, 33 (1996)]; Ciaravino, V. et al.; Mutat. Res.; 353, 95-107 (1995)]. The incidence of myopathy associated with rhabdomyolysis and renal failure is increased subsequent to such treatment [East, C. et al.; N. Engl. J. Med., 318, 47-48 (1998); Pierce L.R. et al.; J. Am. Med. Assoc., 265, 71-75 (1990)]. Also, these HMG-CoA inhibitors block mevalonate production which occurs at an early stage in cholesterol synthetic pathway. Mevalonate is a common precursor for all isoprenoids such as ubiquinones (Co-enzyme Q-10), the dolichols, isopentenyl t-RNA etc. Therefore, long term blockade of mevalonate synthesis leads to Q-10 deficiency. Serum Co-enzyme Q-10 is important for cardiac function [Laaksonen, R. et al., Eur. J. Clin. Pharmacol. 46,313-7 (1994); Bargossi, A.M. et al; Int.J. Clin. Lab. Res., 24, 171-6 (1994)]. The commonest side-effects of fibrates and particularly clofibrate therapy are gastrointestinal upsets including nausea, vomiting, diarrhoea, dyspepsia, flatulence and abdominal discomfort [Oliver, M. F. et al.; Br. Heart J., 40, 1069-1118 (1978)]. Elevated creatine phosphokinase concentration during clofibrate therapy may be associated with a syndrome of muscle pain and weakness. Large-scale long-term studies have demonstrated an increased incidence of cholecystitis, gallstones and sometimes pancreatitis in patients receiving clofibrate and some studies have indicated cardiovascular disorders [The coronary Drug Project Research Group; N. Engl. J. Med., 296, 1185-90 (1977)]. The unexpected finding of an increased mortality rate in patients taking clofibrate in the WHO study produced serious concern over the long-term safety of clofibrate and ultimately led to its withdrawal in many countries [Oliver, M. F. et al; Lancet, ii, 600-604 (1984)].

45 [0004] The adverse effects of biguanidine antidiabetic agents include gastro-intestinal disturbances like diarrhoea and lactic acidosis [Paterson, K. R. et al.; Adverse Drug React Acute Poisoning Rev., 3, 173-82 (1984)]. With sulphonylureas the commonly associated adverse effects are hypoglycemia, gastrointestinal disturbances, hypersensitivity and vascular complications [Paice, B.J. et al., Adverse Drug React. Acute Poisoning, 4, 23-26 (1985)]. As diabetes and hyperlipidemia are quite commonly manifesting together, it would be of great clinical benefit if the same compound could have both these activities together because the available drugs are not free of toxic effects and neither data regarding toxic manifestations are available when drugs for two clinical conditions are mixed together.

50 [0005] Two approaches currently being pursued in search of drugs with hypolipidemic and hypoglycemic activities together. The first approach emerged during detailed study of antihypertensive action of adrenergic receptor modulators. The study revealed that α_1 -adrenergic blockers (particularly Doxazosin and Prazosin) [Lithell, H.O. ; J. Hypertens, 15 (Suppl 1), S 39-42 (1997); Poliare, T. et al.; Diabetologia, 31, 415-420 (1988); Anderson, P.E. et al.; Am. J. Hypertens, 9, 323-333 (1996)] and β_3 -adrenergic agonist (BTA-243, BRL-37344, CGP 12177, CL 316243 [Arch. J. R. S. et al.; Med. Res. Rev., 13, 663-729 (1993); Largis, E. E. et al.; Drug Dev. Res., 32, 69-76 (1994)] also affect plasma lipoprotein

metabolism and increase insulin sensitivity; As a result such antihypertensive drugs exhibit lipid lowering and hypoglycemic actions together, α_1 -adrenergic receptor blockers, however have the inherent limitations of causing orthostatic hypotension and syncope [Matyus, P.; Med. Res. Rev., **17**(6), 523-35 (1997)]. The essential requirement of β_3 -agonist for antiobesity and antidiabetic actions is the need for high selectivity for β_3 -adrenoceptor. Any substantial β_1 - or β_2 -agonism would likely cause increased heart rate and muscle tremor respectively which are unacceptable in a drug which could be administered on long term basis [Connacher, A. A. et al.; Brit. Med. J., **296**, 1217-20 (1988); Mitchell, T. H. et al; Int. J. Obesity., **13**(6), 757-66 (1989)]. The second line of approach for dual activity came into light during the study of anti-oxidant property of drugs. There have been many reports describing relationships between peroxidation and diseases such as diabetes mellitus, atherosclerosis and myocardial ischemia in terms of radical oxidation. Troglitazone, an antioxidant drug has been developed as an oral hypoglycemic agent which enhances the action of insulin in peripheral tissues and liver besides its hypolipidemic effects. However, troglitazone is also not free of major side effect causing liver damage. The drug, troglitazone, has been implicated in 35 cases of liver disease leading to one transplant and one death [Warner-Lambert; Chem. & Ind., No.22, 897 (1997)]. Thus to the best of our knowledge no class of compound is yet available which has both effects together as the main action and have fair safety margin.

[0006] We, in early eighties started our work for search of such compounds which have effect on endogenous transportation of lipids and glucose rather than interfering with exogenous transportation. Our research was mainly based on secondary metabolic actions of progesterone.

[0007] Progesterone, apart from its classical hormonal action on the reproductive system, is known to modulate lipid, carbohydrate, insulin and protein metabolism. The rise in the level of progesterone in the first trimester of pregnancy causes hyperphagia, pancreatic islet hypertrophy, hyperinsulinemia and body fat and glycogen deposition, when the metabolic demands of the fetus are very low. However, in the latter half of pregnancy, although the progesterone levels are still high, the carbohydrate, lipid and protein reservoirs shift into circulation to meet the needs of the growing fetus. [Kalkhoff, R.K.; Am. J. Obstet. Gynecol., **142**, 735-38 (1982)].

[0008] Progesterone thus, having actions both on the reproductive and the metabolic systems, seemed to offer the possibility of dissociating these two biological activities by structural modifications. The experience of the development of second generation progestins supported this contention. The first generation progestins such as levonorgestrel exhibited undesirable pharmacologic effects like alteration in carbohydrate and lipoprotein metabolism, weight gain and hypertension, which was shown to be related to their intrinsic androgenic/anabolic activity and ability to bind with androgen receptors. The androgenic affinity has been attributed to C-17 hydroxy functionality which makes these molecules resemble androgens. In recently discovered second generation progestins such as gestodene and 3-keto-desogestrel, an additional olefinic bond either in C- or D- ring brought a dramatic decrease in their affinity to androgen receptors (Table 1). As a result these compounds have a very high order of progestational effect with practically no androgenic activity and did not cause hyperlipidemia [London, R.S.; Obstetrical & Gynecological Survey, **47**, 777-81 (1992)].

Table 1.

Relative Binding Affinity of Contraceptive Progestins for Progesterone and Androgen receptors			
	Progestin Receptor Binding Affinity	Androgen Receptor Binding Affinity	Selectivity Index* (A/P ratio)
Progesterone	1.00	0.005	93
Levonorgestrel	5.41	0.220	11
3-Keto-desogestrel	8.6	0.120	33
Gestodene	9.21	0.154	28

* The higher the selectivity index, the greater the separation between the dose needed to achieve the desired progestational effect and the dose associated with the undesired androgenic effect [Collins, D.C. Am. J. Obstet. Gynecol. **170**, 1508-13 (1994)].

Objects of the invention

[0009] It is an object of the invention to explore the possibility of designing pregnadienones which while preserving the ability to modulate lipid and carbohydrate metabolism would not have any progestational effect. It would be pertinent to point out that earlier, the applicants had isolated a D-ring modified pregnenolone, named Gugulsterone represented by formula (9) as shown in Table 2, from guggul resin obtained from *Commiphora mukul*, which had potent hypolipidemic effect without any progestational effect [Arya, V.P.; Drugs Fut. **13**, 618 (1998)].

[0010] It is another object of the invention to explore the possibility of dissociating the hypolipidemic and insulin sensitizing activities of progesterone from its hormonal actions. Accordingly, the applicants focussed their attention to

prepare and investigate analogues/prototypes with additional substituents in ring-D of pregnadienones.

Brief description of the accompanying drawings

5 [0011]

Figure 1 (I) represents the structural formula of compounds belonging to the class of pregnadienones and pregnadienols and

10 Figure 1 (II) represents the structural formula of 3 β -hydroxypregna-5, 16-lien-20-one

Figure 2 represents the structural formulae of hormones.

Summary of the invention


15

[0012] In accordance with the above objectives, the applicant's present invention relates to a method of using D-ring unsaturated pregnadienones represented by structural formula I which causes significant fall of serum cholesterol, triglycerides, LDL-cholesterol and glucose with mild increase in HDL-cholesterol, said method comprising administration of effective amounts of said compounds of formula (I) to mammals. The compounds possess fair safety margin having antioxidant and cardio protection activities.

20

[0013] The invention also provides a method of treatment of hypolipidemic and hypoglycemic conditions which comprises administration to a recipient a therapeutic composition comprising a pharmaceutically effective amount of compound D-ring unsaturated pregnadienones represented by the general formula I as shown hereinbelow and in the accompanying drawings:

25



30

35

Wherein X= OH or O or combination thereof and positioning of olefinic bonds are at 4(5); 5(6); 16(17); 17(20) or various combinations

40

Detailed description of the invention


[0014] The present invention concerns methods for lowering serum cholesterol, triglycerides and glucose levels in subjects with obesity and diabetic conditions or prophylactically holding in check the symptoms of such a disease state.

45

[0015] In particular, the applicants, during their study, have observed that the pregnadienone, 3 β -hydroxypregna-5, 16-dien-20-one represented by the structural formula (II) shown hereinbelow and in the accompanying drawings is useful for the treatment of hypolipidemic and hypoglycemic conditions.

50

55



II

[0016] Accordingly, the invention provides a method of using compounds represented by the structural formula (I) as shown in the accompanying drawings, containing at least one olefinic bond in or on their D-ring for the treatment of hypolipidemic and hypoglycemic conditions in mammals, said method comprising administering an effective amount of the said compounds to recipient mammals.

[0017] In one embodiment, the compounds of formula (I) are administered in the form of tablets, capsules or injectibles.

[0018] In another embodiment, the compounds of formula (I) are characterised as pregnadienones and pregnadienols.

[0019] In yet another embodiment, the most preferred compound belonging to the family of pregnanienones and pregnadienols represented by formula (I) is 3β-hydroxy-pregna-5,16-dien-20-one, which is represented by the structural formula (II) as shown in the accompanying drawings.

[0020] In a further embodiment, the compounds of formula (I) are optionally administered to the recipient mammal as an admixture with conventional anti-platelet, anti atherosclerotic, hypolipoproteinemic and antidiabetic drugs.

[0021] In still another embodiment, the compounds of formula (I) are essentially free of side effects associated with conventional hypolipidemic and hypoglycemic drugs.

[0022] In an embodiment, the compounds of formula (I) exhibit cardioprotective, anti-diabetic, anti-atherosclerotic and anti-oxidant properties.

[0023] Further, the invention provides a method of treatment of hypolipidemic and hypoglycemic conditions in mammals, which comprises administration to a recipient, a therapeutic composition comprising an effective amount of compound of formula (I) with conventional carriers.

[0024] In an embodiment, the recipient mammals are selected from the group comprising rats, human beings, rhesus monkeys and rabbits.

[0025] In another embodiment, the conventional carriers are selected from anti-platelet, anti-atherosclerotic, hypolipoproteinemic and anti-diabetic drugs.

[0026] In yet another embodiment, the said compounds of formula (I) essentially contain an olefinic bond in or on their D-ring.

[0027] In a further embodiment, the compounds of formula (I) are essentially free of androgenic, progestinal and side effects.

[0028] In still another embodiment, the therapeutic composition is administered in the form of tablets, capsules and injectibles.

[0029] In another embodiment, the said pregnadienones and pregnadienols exhibit cardio protective, antidiabetic, antialtherosclerotic and antioxidant properties.

[0030] In yet another embodiment, the said pregnadienones and pregnadienols of formula I essentially contain olefinic bond in one of the D-rings.

Methods of synthesis/production

[0031] 3β-Hydroxy pregna-5, 16-dien-20-one The methods of synthesis are essentially known in the literature/can be obtained from diosgenin by chemical degradation [G. Rosenleranz "History of Steroids", Steroids, 57, 409 (1992)]. Although, it was later isolated from Veratrum Grandiflorum [Kanko, K. et al; Phytochemistry, 12 1509 (1973)] but yield is too low to be of any practical value. Oppenauer oxidation of **2** with aluminium-isopropoxide and cyclohexanone in toluene produces 4,16-dienpregna-3,20-dione [16-dehydropregesterone, (**3**)]. The C-16(17)olefinic bond in **1** is selectively reduced with Pd-C in diethylether at very low hydrogen gas pressure. The resultant product **4** on basic hydrolysis furnishes **5**. The procedure of Benn and Dodson (J. Org. Chem. **29**, 1142 (1964)) was followed for the preparation of Gugulsterone (**9**). The reduction of 16-DPA (**1**) with lithium aluminium hydride produces diol **6** which after Sigmatropic rearrangement in presence of p-toluenesulphonic acids acetic acid and acetic anhydride produces the diacetate **7**. Basic hydrolysis of the diacetate **7** followed by Oppenauer oxidation furnishes an 80 : 20 mixture of E&Z- Gugulsterone

(9).



5. BIOLOGICAL ACTIVITY**5.1 Hypolipidemic Activity**







[0032] The primary hypolipidemic effect of these compounds were established in triton induced hyperlipidemia in Charles Foster rats. The compounds which exhibited significant lipid lowering effect in this model were then evaluated for their hypolipidemic effect in normal, and diet induced hyperlipidemic rats, rabbits and rhesus monkeys.


5.1.1. Hypolipidemic Activity In Triton Treated Rats

[0033] The cholesterol lowering effect of some representative compounds of pregnenadienols and -pregnenadienones as compared to clofibrate and guggulsterone in triton treated Charles Foster rats is described in Table-2

Table-2 : Cholesterol lowering effect of pregnane compounds as compared to Clofibrate in Triton treated rats

Compd. No.	Compound	Structure	Dose (i.p.) mg/kg	% Change S. Chol.
1	3 β -Acetoxypregna-5,16-dien-20-one (16-DPA)		50	-43
2	3 β -Hydroxypregna-5,16-dien-20-one		50	-46

3	4,16-Dienpregna-3,20-dione		50	-13
4	3 β -Acetoxypregna-5-en-20-one		100	-12
5	3 β -Hydroxypregna-5-en-20-one		100	-09
6	5,16-Dien-pregnane-3,20-diol		50	-10
7	5,17(20)-Dienpregna-3,16-diol-diacetate		50	-33
8	5,17(20)-Dienpregna-3,16-diol		50	-31

9	Gugulsterone		50	-44
10	Clofibrate		200	-15

[0034] The results showed that of the compounds tested, the highest effect was exhibited by 16-DPA (1) and its 3-des-acetyl analog 2 comparable to gugulsterone (9), and that the removal of double bond in ring D of 1 or 2 almost abolished the effect.

5.1.2 Hypolipidemic Activity of 3 β -Hydroxypregna-5,16-dien-20-one (2) in Normal Rats

[0035] In normal rats, 3 β -hydroxypregna-5,16-dien-20-one (2), at 50 mg/kg produced a significant lowering of serum cholesterol and triglycerides as describe in Table-3 below. The animals did not develop any tolerance to the compound even after administering for 30 days.

Table 3.

Hypolipidemic activity of 3 β -Hydroxypregna-5,16-dien-20-one (2) in normal rats					
Treatment	Serum Cholesterol (mg%)		%Fall	Serum Triglycerides (mg%) 30 Days	% Fall compared to control
	0 Days	30 Days			
2(50mg/kg) (8)	71.5 \pm 1.8	43.2 \pm 2.9	40 40	42.0 \pm 2.8	35
Clofibrate (50 mg/kg) (6)	82.3 \pm 3.3	53.2 \pm 2.0	36	47.3 \pm 3.2	28
Normal saline (control) (6)	83.3 \pm 3.1	80.1 \pm 1.4	-	65.2 \pm 2.9	-
Mean values \pm SD. Figure in parenthesis represent number of animals.					

5.1.3 Hypolipidemic Activity in Diet Induced Hyperlipidemic Rats

[0036] Twenty three normal male rats average weight 110-120 g were taken for study and were divided into four groups. Group I: animals received special diet and 3 β -hydroxypregna-5, 16-dien-20-one (2) 50 mg/kg p.o. in 1% gum acacia. Group II: animals received 3 β -hydroxypregna-5, 16-dien-20-one (2), 100 mg/kg p.o. in 1% gum acacia and special diet. Group III: animals received special fat diet and 1% gum acacia and served as control. Group IV: animals were fed with stock diet and served as normal control. All animals were sacrificed at the end of 36 days. Blood was drawn from the tail at 10 days and from the aorta at the time of sacrifice for estimation of serum cholesterol, triglycerides and HDL-cholesterol. LDL-cholesterol was calculated as described.

[Roschlau, P. In: Methods of Enzymatic Analysis 4th ed., H.U. Bergmeyer, Ed (Academic Press, New York) 1975 p 1890; Wahlefield, W.A. In: Methods of Enzymatic Analysis, 4th ed.; H.U. Bergmeyer, Ed. (Academic Press, New York) 1974 p 1831.]

Results

[0037] Animals treated with 3 β -hydroxypregna-5, 16-dien-20-one (2), at 50 and 100 mg/kg showed a significant lowering in serum cholesterol by 31 and 59%, triglycerides by 55 and 62%. LDL-cholesterol by 27 and 74% respectively (Table - 4 & 5).

5.6. PROGESTATIONAL AND ANTIPROGESTATIONAL ACTIVITY

[0049] The relative affinity of compounds for cytoplasmic progesterone receptors present in human breast tumour cells (MCF-7) were estimated and compared with 16-ethyl-21-hydroxy-19-norpregna-4-ene-3,20-dione (Org 2058). The experiments conducted revealed that the compounds 2,3 and 5 have no or only negligible binding affinity.

[0050] The progestational activity was also tested *in vivo* by Clauberg assay method. The degree of endometrial proliferation was estimated on the McPhail scale where 3' or 4' was considered as a full progestational effect, 3 β -Hydroxypregna-5,16-dien-20-one (2) did not exhibit any activity even at 200 mg/kg dose, whereas progesterone showed, as expected marked progestational activity even at 50 mg/kg.

Claims

1. Use of a compound represented by the structural formula (I) as shown in the accompanying drawings, containing at least one olefinic bond in or on their D-ring in the manufacture of a medicament for the treatment or prophylaxis of a hypolipidemic and/or hypoglycemic condition.
2. Use of a compound represented by the structural formula (I) as shown in the accompanying drawings, containing at least one olefinic bond in or on their D-ring in the manufacture of a medicament for the treatment or prophylaxis of a diabetic condition.
3. Use of a compound represented by the structural formula (I) as shown in the accompanying drawings, containing at least one olefinic bond in or on their D-ring in the manufacture of a medicament for lowering serum cholesterol, triglyceride and/or glucose levels in a subject with obesity or a diabetic condition.
4. Use as claimed in any of claims 1 to 3, wherein the compound of formula (I) is characterised as a pregnadienone or pregnadienol.
5. Use as claimed in any of claims 1 to 4, wherein the compound of formula (I) is 3 β -hydroxy-pregna-5,16-dien-20-one, which is represented by the structural formula (II) as shown in the accompanying drawings.
6. Use as claimed in any of claims 1 to 5, wherein a compound of formula (I) is optionally administered as an admixture with one or more other therapeutic agents selected from anti-platelet, anti-atherosclerotic, hypolipoproteinemic and antidiabetic drugs.
7. Use as claimed in any of claims 1 to 5 wherein the medicament is in the form of a tablet, capsule or injectible.
8. A compound of formula (I) for use in the treatment of a hypolipidemic and/or hypoglycemic condition.




Figure 1 (I)







Figure 1 (II)




PROGESTERONE




NORETHISTERONE




LEVONORGESTREL



GESTODENE



3-KETODESOGESTREL



GUGULSTERONE



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 2556

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	BEG M ET AL: "A study of effect of #guggulsterone# on hyperlipidemia of secondary glomerulopathy." INDIAN J PHYSIOL PHARMACOL, JUL 1996, 40 (3) P237-40, XP002118411 INDIA	1,3,7,8	A61K31/57 C07J13/00 C07J7/00
A	* the whole document * ---	6	
X	DATABASE MEDLINE 'Online! Dialog AN:2603885 MEDLINE AN= 79088643, XP002118423 * abstract * & KUPPURAJAN ET AL.: "Effect of guggulu (Commiphora mukul-Engl.) on serum lipids in obese, hypercholesterolemic and hyperlipemic cases" J. ASSOC. PHYSICIANS INDIA, vol. 26, no. 5, May 1978 (1978-05), pages 367-373,	1,3,8	
A	* abstract * ---	6	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	SINGH K. ET AL: "#Guggulsterone#, a potent hypolipidaemic, prevents oxidation of low density lipoprotein" PHYTOTHERAPY RESEARCH_(PHYTOTHER. RES.), 11/4 (291-294), XP002118412 United Kingdom * page 291, left-hand column, paragraph 1 * * abstract * --- -/--	1,6,8	A61K C07J
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11 October 1999	Examiner Gac, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 2556

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	SINGH RB ET AL: "Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia." CARDIOVASC DRUGS THER, AUG 1994, 8 (4) P659-64, XP002118413 UNITED STATES	1,7,8	
A	* the whole document, especially page 659 and page 663 right column; page 664 structure of compounds * ---	6	
X	CHEMICAL ABSTRACTS, vol. 129, no. 8, 24 August 1998 (1998-08-24) Columbus, Ohio, US; abstract no. 090097, GAUR, S. P. S. ET AL: "Gugulipid, a new hypolipidemic agent, in patients of acute ischemic stroke: effect on clinical outcome, platelet function and serum lipids" XP002118420 * abstract *	1,8	
A	* the whole document * & ASIA PAC. J. PHARMACOL., 1997, 12, 65-69, ---	6	
X	MESTER L ET AL: "Inhibition of platelet aggregation by "guggulu" steroids." PLANTA MED, DEC 1979, 37 (4) P367-9, XP002118414 GERMANY, WEST	1,8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	* the whole document * ---	6	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11. October 1999	Examiner Gac, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03 82 (P4/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 2556

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	CHANDER R. ET AL: "Lipid lowering activity of #guggulsterone# from Commiphora mukul in hyperlipaemic rats" PHYTOTHERAPY RESEARCH_(PHYTOTHER. RES.), 10/6 (508-511), XP002118415 United Kingdom	1,8	
A	* the whole document *	3	
X	KAPOOR N K ET AL: "PROTECTION BY #GUGGULSTERONE# A HYPOLIPIDEMIC DRUG AGAINST BIOCHEMICAL CHANGES IN ISCHEMIC HEART MEMBRANE INDUCED BY ISOPROTERENOL" SYMPOSIUM ON THE PHARMACOLOGIC MECHANISMS AND HEART DISEASE HELD AT THE XIIITH CONGRESS OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH AND THE ELEVENTH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH (AMERICAN SECTION), ANN ARBOR, MIC, XP002118416 * abstract *	1,8	
X	MOGHE, V. V._DALVI, S. S._JOSHI, M. V._KSHIRSAGAR, N. A._GUPTA, K. C.: "EFFECT OF PRE-TREATMENT AND CONCOMITANT ADMINISTRATION OF GUGULIPID ON ABSORPTION OF ORAL DIGOXIN" INDIAN J. HOSP. PHARM., September 1994 (1994-09) - October 1994 (1994-10), pages 172-174, XP002118417	1,8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	* the whole document *	6	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11 October 1999	Examiner Gac, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04/001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 2556

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	CHEMICAL ABSTRACTS, vol. 75, no. 13, 27 September 1971 (1971-09-27) Columbus, Ohio, US; abstract no. 088824, NAMBARA, TOSHIO ET AL: "Cardiotonic steroid analogs. X. Reactions of 5.alpha.,14.beta.-pregn-16-en-20-one with nucleophiles" XP002118421 * abstract *	8	
A	* page 1138 compounds VI and VIIa and VIIb * & CHEM. PHARM. BULL., 1971, 19, 1137-43, ---	4	
X	CHEMICAL ABSTRACTS, vol. 98, no. 23, 6 June 1983 (1983-06-06) Columbus, Ohio, US; abstract no. 194935, BAJAJ, ASHOK G. ET AL: "Chemisry of ayurvedic crude drugs. V. Guggulu (resin from Commiphora mukul). 5. Some new steroidal components and stereochemistry of guggulsterol-I at C-20 and C-22" XP002118422 * abstract * * compounds 1,2,4,12 * & TETRAHEDRON, 1982, 38, 2949-54, ---	8	
X,D	ARYA: "Gugulipid" DRUGS FUTURE, vol. 13, 1988, pages 618-619, XP002118418 * the whole document *	1,8	
A	---	3,7	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11 October 1999	Examiner Gac, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03 82 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 2556

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	EP 0 447 706 A (CIPLA LIMITED) 25 September 1991 (1991-09-25) * the whole document, especially page 2 lines 4-11 *	1,8	
X	US 2 752 370 A (GOULD D.H.) 26 June 1956 (1956-06-26) * column 4 last compound *	8	
A	---	4,5	
X	US 3 475 464 A (HALPERN) 28 October 1969 (1969-10-28) * the whole document *	8	
A	---	4	
X	DE 13 01 999 B (SCHERING AG) * column 2, line 16; example 1 *	8	
A	---	4	
A	BECK: "Effect of progestins on glucose and lipid metabolism" ANN. NEW YORK ACAD. SCI., vol. 286, 1977, pages 434-445, XP002118419 * the whole document *	1-8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 11 October 1999	Examiner Gac, G
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1501 03/92 (Pct/Cn)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 2556

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-10-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 447706	A	25-09-1991	NONE
US 2752370	A	26-06-1956	NONE
US 3475464	A	28-10-1969	NONE
DE 1301999	B	NONE	

EPO FORM P469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82